Skip to main content
Equibles
VNRX logo

VNRX · Volitionrx Ltd · Webcasts, Transcripts & Audio

Track VNRX — free

Use VNRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.25 +0.02 (+6.64%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Customer concentration — top 2 customers 38% of receivables

2 customers — 38% of receivables (At December 31, 2025)

“At December 31, 2025 the two largest customer balances represented over 38% of the total outstanding accounts receivable balance.”
View the 10-K filed Mar 31, 2026
Market Cap
$3.54M
Shares
13.65M
Volume · Oct 6 521.6K Avg daily vol (3M) 8.31M

Volitionrx Ltd Webcasts

Earnings calls, investor updates, investor days and conferences for Volitionrx Ltd (VNRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲60.4% $39,752 −$7.73M '22 Q2 22-08-02 ▲28.4% $32,714 −$7.81M '22 Q3 22-11-14 ▲740.7% $119,715 −$7.34M '22 Q4 23-02-21 ▲31.2% $149,808 −$8.87M '23 Q1 23-05-10 ▲444.1% $216,310 −$9.55M '23 Q2 23-08-14 ▲405% $165,211 −$8.45M '23 Q3 23-11-14 ▲103.8% $243,973 −$8.80M '23 Q4 24-03-25 ▲14.5% $171,535 −$8.37M '24 Q1 24-05-13 ▲83% $395,797 −$6.99M '24 Q2 24-08-14 ▲187.2% $474,522 −$5.82M '24 Q3 24-11-14 ▼21.4% $191,657 −$5.79M '24 Q4 25-03-31 ▲43.6% $246,385 −$5.42M '25 Q1 25-05-15 ▲2.8% $406,688 −$6.28M '25 Q2 25-08-14 ▲32.2% $627,277 −$5.38M '25 Q3 25-10-14 ▲299.8% $985,076 −$6.66M '26 Q1 26-05-15 LATEST ▼2% $398,657 −$7.33M '26 Q2 26-08-14
Earnings call
FY26 · Q2
2026-08-14
Volitionrx Ltd (VNRX) Q2 2026 Earnings Call Transcript
Confident tone NuQ-Nets sepsis product CaptureSeq liquid biopsy technology Partnerships with large diagnostics companies
Revenue
$398,657
▼ 2% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
Volitionrx Ltd (VNRX) Q1 2026 Earnings Call Transcript
Positive tone Licensing and commercialization Capture-C pipe Financial position and cost control
Revenue
$985,076
▲ 299.8% YoY
Diluted EPS
$-0.97
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-10-14
Volitionrx Ltd (VNRX) Q3 2025 Earnings Call Transcript
Positive tone Werfen APS Licensing Agreement Capture-Seq Liquid Biopsy Technology Hologic Diagenode Co-Marketing Agreement
Revenue
$627,277
▲ 32.2% YoY
Diluted EPS
$-1.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Volitionrx Ltd (VNRX) Q2 2025 Earnings Call Transcript
Confident tone Revenue growth and first human product sales Nu.Q NETs sepsis and disease applications Taiwan screening program implementation
Revenue
$406,688
▲ 2.8% YoY
Diluted EPS
$-1.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Volitionrx Ltd (VNRX) Q1 2025 Earnings Call Transcript
Confident tone Human diagnostics commercialization Sepsis / Nu.Q NETs pillar Licensing deals and partnerships
Revenue
$246,385
▲ 43.6% YoY
Diluted EPS
$-1.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Volitionrx Ltd (VNRX) Q4 2024 Earnings Call
Revenue
$191,657*
▼ 21.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Volitionrx Ltd (VNRX) Q3 2024 Earnings Call Transcript
Confident tone Sepsis and Innovation Lab Lung Cancer Diagnostics Feline Test Development
Revenue
$474,522
▲ 187.2% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Volitionrx Ltd (VNRX) Q2 2024 Earnings Call Transcript
Positive tone Human oncology licensing pursuit Sepsis program (Nu.Q NETs / H3.1) Cost reduction program
Revenue
$395,797
▲ 83% YoY
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Volitionrx Ltd (VNRX) Q1 2024 Earnings Call Transcript
Positive tone Nu.Q NETs and Sepsis clinical data Capture-PCR and platform adaptability Non-dilutive funding pursuit
Revenue
$171,535
▲ 14.5% YoY
Diluted EPS
$-2.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Volitionrx Ltd (VNRX) Q4 2023 Earnings Call Transcript
Positive tone Human Sepsis - Nu.Q NET and Capture-PCR Financial Position and Cash Runway Human Licensing Deals Pipeline
Revenue
$243,973*
▲ 103.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Volitionrx Ltd (VNRX) Q3 2023 Earnings Call Transcript
Revenue
$165,211
▲ 405% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Volitionrx Ltd (VNRX) Q2 2023 Earnings Call Transcript
Revenue
$216,310
▲ 444.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Volitionrx Ltd (VNRX) Q1 2023 Earnings Call Transcript
Revenue
$149,808
▲ 31.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Volitionrx Ltd (VNRX) Q4 2022 Earnings Call Transcript
Revenue
$119,715*
▲ 740.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Volitionrx Ltd (VNRX) Q3 2022 Earnings Call Transcript
Revenue
$32,714
▲ 28.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Volitionrx Ltd (VNRX) Q2 2022 Earnings Call Transcript
Revenue
$39,752
▲ 60.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Volitionrx Ltd (VNRX) Q1 2022 Earnings Call Transcript
Revenue
$114,211
▲ 347.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
Volitionrx Ltd (VNRX) Q4 2021 Earnings Call Transcript
Revenue
$14,240*
▲ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Volitionrx Ltd (VNRX) Q3 2021 Earnings Call Transcript
Revenue
$25,483
▲ 4331.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Volitionrx Ltd (VNRX) Q2 2021 Earnings Call Transcript
Revenue
$24,782
▲ 377.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Volitionrx Ltd (VNRX) Q1 2021 Earnings Call Transcript
Revenue
$25,530
▲ 4593% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-22
Volitionrx Ltd (VNRX) Q4 2020 Earnings Call Transcript
Revenue
$7,120*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Volitionrx Ltd (VNRX) Q3 2020 Earnings Call Transcript
Revenue
$575
▼ 96.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Volitionrx Ltd (VNRX) Q2 2020 Earnings Call Transcript
Revenue
$5,194
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Volitionrx Ltd (VNRX) Q1 2020 Earnings Call Transcript
Revenue
$544
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Volitionrx Ltd (VNRX) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 webcasts
Key facts CIK 93314 CUSIP 928661206 13F (30d) 2 filings 2 filers Visit website Investor relations